TITLE

Two Endogenous Antiangiogenic Inhibitors, Endostatin and Angiostatin, Demonstrate Biphasic Curves in Their Antitumor Profiles

AUTHOR(S)
Javaherian, Kashi; Lee, Tong-Young; Sjin, Robert M. Tjin Tham; Parris, George E.; Hlatky, Lynn
PUB. DATE
July 2011
SOURCE
Dose-Response;2011, Vol. 9 Issue 3, p369
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Angiogenesis refers to growth of blood vessels from pre-existing ones. In 1971, Folkman proposed that by choking off the blood supply to tumors, they are starved, leading to their demise. A few years ago, the monoclonal antibody Avastin became the first antiangiogenic biological approved by FDA, for treatment of cancer patients. Two other antiangiogenic endogenous protein fragments were isolated in Folkman's laboratory more than a decade ago. Here, we present a short review of data demonstrating that angiostatin and endostatin display a biphasic antitumor dose-response. This behavior is common among a large number of antiangiogenic agents and the reduced effectiveness of antiangiogenic agents at high dose rates may be due to suppression of growth of new vessels carrying the agent into the critical region around the tumor.
ACCESSION #
67699242

 

Related Articles

  • Emerging Role of Apelin as a Therapeutic Target in Cancer: A Patent Review. Rayalam, Srujana; Della-Fera, Mary A.; Kasser, Thomas; Warren, William; Baile, Clifton A. // Recent Patents on Anti-Cancer Drug Discovery;Sep2011, Vol. 6 Issue 3, p367 

    Since tumors cannot grow or spread without forming new blood vessels, inhibiting angiogenesis is an excellent approach for the treatment of cancer. Further, inhibitors of angiogenesis have mild side effects since they act on endothelial cells, which eliminate the possibility of developing...

  • POINT/COUNTER. Soliman, Hatem; Ko, Andrew // Hem/Onc Today;5/25/2011, Vol. 12 Issue 10, p11 

    The article presents different views on whether the drug bevacizumab has fulfilled expectations, citing one's view that bevacizumab has mixed results and the other noting that the drug is an outstanding achievement in oncology.

  • Angiogenesis Inhibitors and Vascular Disrupting Agents in Non-Small Cell Lung Cancer. Rossi, A.; Maione, P.; Ferrara, M. L.; Sacco, P. C.; Schettino, C.; Bareschino, M. A.; Gridelli, C. // Current Medicinal Chemistry;Oct2009, Vol. 16 Issue 30, p3919 

    Most patients diagnosed with non-small cell lung cancer (NSCLC) have advanced disease. Chemotherapy has apparently reached a plateau of effectiveness in improving survival in this subgroup of patients. Considerable efforts have been initiated to identify novel targets for new biological agents...

  • Extrafoveal changes following intravitreal bevacizumab injections for macular edema secondary to branch retinal vein occlusion: an mfERG and OCT study. Park, Saemi; Cho, In; Park, Tae; Nam, Woo; Ohn, Young-Hoon // Documenta Ophthalmologica;Apr2013, Vol. 126 Issue 2, p137 

    Purpose: To evaluate the functional and structural changes of extrafoveal macula after intravitreal bevacizumab (IVB) injection in patients with macular edema due to branch retinal vein occlusion (BRVO) using multifocal electroretinogram (mfERG) and optical coherence tomography (OCT). Methods: A...

  • Acute sterile endophthalmitis following intravitreal bevacizumab: case series. Orozco-Hernández, Axel; Ortega-Larrocea, Ximena; Sánchez-Bermúdez, Gustavo; García-Aguirre, Gerardo; Cantón, Virgilio Morales; Velez-Montoya, Raul // Clinical Ophthalmology;2014, Vol. 8, p1793 

    Background: Since the ophthalmological community adopted the use of intravitreal bevacizumab as an accepted off-label treatment for neovascular diseases, the amount of knowledge regarding its effects and properties has been increasing continually. In the last few years, there have been an...

  • Bevacizumab in lung cancer: Lackluster performance and unjustified expense? Dasanu, Constantin A // Journal of Oncology Pharmacy Practice;Sep2012, Vol. 18 Issue 3, p381 

    A recent retrospective analysis of a large cohort of patients aged 65 and older with advanced non-small cell lung cancer failed to demonstrate any improvement in survival with the addition of bevacizumab to the platinum doublet in the first-line therapy. A few points have to be made: 1) a vast...

  • Long-term results of intravitreal ranibizumab for osteoma-related choroidal neovascularization in a child. Gupta, Aditi; Gopal, Lingam; Sen, Parveen; Ratra, Dhanashree; Rao, Chetan // Oman Journal of Ophthalmology;Jun2014, Vol. 7 Issue 2, p78 

    Though choroidal osteoma is a rare benign tumor, associated choroidal neovascularization (CNV) can be a cause of severe visual loss. A nine-year-old boy presented with one-month history of decreased vision in left eye. Upon a complete ophthalmologic examination, including fundus fluorescein...

  • The Matrix Reloaded: New Insights from Type IV Collagen Derived Endogenous Angiogenesis Inhibitors and their Mechanism of Action. Sudhakar, Akulapalli // Journal of Bioequivalence & Bioavailability;Jul-Aug2009, Vol. 1 Issue 2, p52 

    Angiogenesis, the process of neovascularization from parent blood vessels, is a prerequisite for many physiological and pathological conditions that is regulated by a balance between the levels of endogenous angiogenic stimulators and matrix reloaded angiogenic regulators. Several...

  • Cancer Drugs in Pipeline Span Wide Spectrum. McCann, Jean // JNCI: Journal of the National Cancer Institute;03/21/2001, Vol. 93 Issue 6, p424 

    Reports on the development of methods for targeting cancer cells with good precision and less toxicity. Apoptosis induction; Monoclonal antibodies for cancer treatment; Angiogenesis inhibiting drugs; Breast cancer drugs and cancer vaccines. INSET: Incidence Rates by Age at Diagnosis for Breast...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics